News

ATCC Receives Contract to Advance Industrial Biomanufacturing and Produce Synthetic Aviation Fuel Precursors

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been granted a contract with Capra Biosciences, a Virginia-based biotech company focused on the cost-competitive production of petrochemical replacements using its modular bioreactor platform. ATCC is supporting a contract with Capra to work on the Defense Advanced Research Projects Agency’s (DARPA) Switch program. This initiative directly supports growth of the U.S. bioeconomy and aligns with the National Security Commission on Emerging Biotechnology’s recent call for accelerated investment in biomanufacturing to strengthen national security, economic resilience, and global competitiveness. By advancing innovative microbial engineering and feedstock-flexible biomanufacturing, the project will help catalyze U.S. leadership in biotechnology innovation, enabling scalable, locally produced alternatives to petroleum-based products and reinforcing the nation’s position at the forefront of the global bioindustrial revolution.

Currently, the U.S. Department of Defense (DoD) relies on petrochemicals as the source of carbon-containing molecules required for virtually every aspect of its operations – they are the building blocks for diverse products such as food, pharmaceuticals, fuel, textiles, and more. Petrochemical manufacturing is dependent on foreign supply chains, and its manufacturing practices lack agility and reproducibility. Alternative technologies, like biomanufacturing, can produce similar organic commodities to petrochemicals, but they are developed to optimize yield at the cost of flexibility and only produce a single commodity. Switch aims to create a suite of tools and approaches to engineer run-time reprogrammable microorganisms that support a variety of possible biomanufacturing processes that will have greater supply chain security, flexibility of input/output, and reduced costs, as well as sustainability. The program will enable four Concepts of Operations (CONOPS) for biomanufacturing that provide novel capabilities for national security.

Capra, the primary contractor, is focused specifically on one CONOPS – ‘opportunistic consumption’ by switching between feedstocks – and is collaborating with ATCC, Virginia Tech, Syracuse University, and Next Rung Technology on a unique innovative solution. This project, known as Transcriptomics and OptoGenetics for Lipid Expression (TOGLE), will enable real-time process control based on feedstock composition using a single organism. The TOGLE team will leverage ATCC’s extensive library of microbial strains, as well as its expertise in functional genomics and transcriptomics, to identify genetic components with desired traits. These components will be metabolically engineered into the yeast Yarrowia lipolytica to switch between at least 16 different feedstocks to synthesize free fatty acids, as a precursor for synthetic aviation fuel or lubricants for the DoD. Y. lipolytica was chosen as the base organism because of its versatility and robustness in various industrial applications. Base strains developed as part of this initiative will be available to the scientific community through ATCC’s culture collection.

“This collaboration with Capra is our first in industrial biomanufacturing and we believe that we are well equipped to help researchers navigate and overcome complex problems in this area,” said ATCC Federal Solutions Senior Vice President Rebecca Bradford, MBA, MS, PMP. “With our expansive biorepository, scientists have the capability to use our strains to design and potentially develop new and unique metabolic pathways that can be optimized for biochemical production.”

ATCC has developed robust computational tools for identifying genes associated with infection in transcriptomics datasets. These tools will be adapted as part of this project with Capra to identify genes and gene clusters associated with feedstock metabolism. Additionally, the ATCC Genome Portal is a database of 5,500 high-quality reference genomes from authenticated microbial strains in the ATCC collection. Through this cloud-based platform, researchers can easily access and securely download meticulously curated whole-genome sequences to confidently perform bioinformatics analyses and make insightful correlations.

The success of this project will yield a new capability to rapidly switch bioproduction among feedstocks at the point of need that will be ready to be scaled to pilot manufacturing and/or tested in mission-relevant environments in Capra’s bioreactor platform.

“By contributing our well-characterized strains for biomanufacturing and in-house expertise in genomics and bioinformatics, we are helping to not only drive innovation in industrial biomanufacturing but also catalyze growth in the U.S. bioeconomy,” said ATCC President and Chief Executive Officer Ruth R. Cheng, PhD.

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation